<DOC>
	<DOCNO>NCT00762983</DOCNO>
	<brief_summary>The purpose study collect information unexpected adverse reaction ( ADRs ) , often ADRs occur , factor affect safety effectiveness Claritin ( loratadine ) use child . Patients observe take Claritin , ADRs symptom score record . At end treatment , improvement symptom record . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Observation Use Claritin ( Loratadine ) Tablet , RediTabs , Dry Syrup Children ( Study P05834 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Pediatric patient age 3 15 year treat Claritin follow reason : allergic rhinitis , urticaria , itch due skin disease ( eczema , dermatitis , pruritus cutaneous ) ( None )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>